Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Diagnostics CEOs In Triplicate Weigh In On Upcoming Hurdles

Executive Summary

Tune in to this one-off podcast feature discussing the state-of-play in the diagnostics sector, with guests from ImmunExpress, Lucid Diagnostics and ChromaCode. 

During this podcast, Medtech Insight speaks to Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis; Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung cancer; and Lishan Aklog, CEO of Lucid Diagnostics, w developed a cell-collection method that aims to bring forward the stage at which esophageal cancer can be diagnosed.

The trio discuss the companies’ products and why they are transformative, as well as the upcoming regulatory and commercial hurdles awaiting diagnostics companies.


  • 1:25. Introductions from Rollie Carlson, Lishan Aklog and Mark McDonough 
  • 5:40. Recent company updates from ImmunExpress and Lucid Diagnostics 
  • 8:30. False positives, false negatives – their importance in difference diagnostic applications 
  • 16:17. Broad commercial themes for 2024 
  • 22:40. The raw deal that diagnostics receives – what's going on with pricing? 
  • 32:00. LDT rule change – who is it good for, and who is it bad for? 
  • 41:10. 2024 – anything to look forward to?

Listen to the podcast via the player below:



Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts